
Quarterly report 2024-Q2
added 08-12-2024
Vapotherm Revenue 2011-2026 | VAPO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Vapotherm
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68.7 M | 66.8 M | 113 M | 126 M | 48.1 M | 42.4 M | 35.6 M | 30.1 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 126 M | 30.1 M | 66.3 M |
Quarterly Revenue Vapotherm
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.9 M | 19.1 M | - | 15.2 M | 16 M | 17.7 M | - | 13.5 M | 13 M | 21.6 M | - | 38.1 M | 20.6 M | 32.3 M | 40.9 M | 30.6 M | 35.2 M | 19.1 M | 13 M | 10.8 M | 12 M | 12.3 M | 11.7 M | 9.39 M | 10.6 M | 10.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 40.9 M | 9.39 M | 19.1 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Electromed
ELMD
|
64 M | $ 25.52 | -0.85 % | $ 216 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.97 | -5.18 % | $ 1.2 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 13.01 | -2.77 % | $ 1.76 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.22 | -0.45 % | $ 49.6 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 11.67 | -2.02 % | $ 462 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.43 | 4.57 % | $ 128 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 178.73 | -2.26 % | $ 12.6 B | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.62 | 3.33 % | $ 38.6 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 10.52 | -5.05 % | $ 298 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Globus Medical
GMED
|
2.94 B | $ 89.25 | -1.61 % | $ 12.1 B | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.1 | -2.33 % | $ 5.82 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
TELA Bio
TELA
|
80.3 M | $ 0.77 | -0.83 % | $ 36.1 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
TransMedics Group
TMDX
|
605 M | $ 100.9 | -0.36 % | $ 3.43 B | ||
|
Tandem Diabetes Care
TNDM
|
290 M | $ 18.19 | -2.36 % | $ 1.24 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.92 | -4.65 % | $ 1.04 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.09 | -0.33 % | $ 354 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 10.31 | -2.27 % | $ 369 M | ||
|
Varex Imaging Corporation
VREX
|
845 M | $ 11.47 | -4.97 % | $ 475 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.04 | - | $ 17.6 M | ||
|
Vivos Therapeutics
VVOS
|
17.4 M | $ 0.81 | -4.1 % | $ 8.32 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.03 | -2.07 % | $ 1.12 B | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 59.54 | -2.86 % | $ 3.25 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 53.69 | -2.58 % | $ 1.58 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.36 | 0.19 % | $ 64.1 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 84.0 | -0.76 % | $ 2.92 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M |